
Cecilia Jiménez Mallebrera
Jefe de Grupo Senior
Research group
Researcher Cecilia Jiménez graduated in Biology from the University of Navarra and from the University of Buckingham in 1996 and earned her PhD in Genetics from the University of London (UCL) in 2001. In 2005, she obtained the degree of Clinical Scientist for the Health and Care Professions Council of the United Kingdom.
Between 2001 and 2010, she undertook a postdoctoral stay at the Dubowitz Neuromuscular Center (now in Great Ormond Street Hospital, London) and the Dept. Of Neuropathology at the Charing Cross Hospital, London where she specialized in neuromuscular pathologies and in the genetics and mechanisms of congenital muscular dystrophies.
She is a member of the European networks EURO-NMD and Treat-NMD and CIBERER.
In 2010, she joined as Researcher Miguel-Servet and group leader at the FSJD.
She is currently leading the group of applied research in neuromuscular diseases whose main objectives are to deepen the mechanism by which neuromuscular diseases occur, to improve the diagnosis of patients by identifying new biomarkers and methodologies and to investigate advanced therapies based, among others, on the genetic edition.
Professional network profiles
Related websites
Last Publications
- Luque J, Mendes I, Gómez B, Morte B, de Heredia ML, Herreras E, Corrochano V, Bueren J, Gallano P, Artuch-Iriberri R, Fillat C, Pérez-Jurado LA, Montoliu L, Carracedo Á, Millán JM, Webb SM, Palau F, CIBERER Network and Lapunzina P CIBERER: Spanish national network for research on rare diseases: A highly productive collaborative initiative CLINICAL GENETICS . 101(5-6): 481-493.
- Almici E, Chiappini V, López-Márquez A, Badosa-Gallego MC, Blázquez B, Caballero D, Montero J, Natera-de Benito D, Nascimento-Osorio A, Roldán M, Lagunas A, Jimenez-Mallebrera C and Samitier J Personalized in vitro Extracellular Matrix Models of Collagen VI-Related Muscular Dystrophies Frontiers in Bioengineering and Biotechnology . 10: 851825-851825.
- López-Márquez A, Morín M, Fernández-Peñalver S, Badosa-Gallego MC, Hernández-Delgado A, Natera-de Benito D, Ortez-Gonzalez CI, Nascimento-Osorio A, Grinberg-Vaisman DR, Balcells S, Roldán M, Moreno-Pelayo MÁ and Jimenez-Mallebrera C CRISPR/Cas9-Mediated Allele-Specific Disruption of a Dominant COL6A1 Pathogenic Variant Improves Collagen VI Network in Patient Fibroblasts INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES . 23(8): .
Projects
- Project name:
- Movilidad de profesionales sanitarios e investigadores del SNS (M-BAE)
- Leader
- Cecilia Jiménez Mallebrera
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- BA21/00010
- Starting - finishing date:
- 2022 - 2022
- Project name:
- Emerging biomarkers for spinal muscular atrophy
- Leader
- Cecilia Jiménez Mallebrera
- Funding entities:
- Biogen International GmbH
- Code
- ES-SPN-1188
- Starting - finishing date:
- 2021 - 2023
- Project name:
- Medicina Personalizada para las Distrofias Musculares Congénitas: Desarrollo de terapias avanzadas, modelos fisiológicos y herramientas diagnósticas precisas
- Leader
- Cecilia Jiménez Mallebrera
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- PI19/00122
- Starting - finishing date:
- 2020 - 2022
News
-
Sant Joan de Déu participates in the new Barcelona Medical Photonics Network
Eight prominent health institutions in the Barcelona area, their research institutes and ICFO join forces through the creation of a network to bring cutting-edge photonic technologies to hospitals.
-
Institut de Recerca Sant Joan de Déu and ICFO create a joint lab to improve neonatal and paediatric health care
The new joint laboratory will advance the use and development of photonic technologies to understand, diagnose, monitor and treat paediatric diseases.